ZA200404023B - Formulations for use in medical or diagnostic procedures. - Google Patents
Formulations for use in medical or diagnostic procedures. Download PDFInfo
- Publication number
- ZA200404023B ZA200404023B ZA200404023A ZA200404023A ZA200404023B ZA 200404023 B ZA200404023 B ZA 200404023B ZA 200404023 A ZA200404023 A ZA 200404023A ZA 200404023 A ZA200404023 A ZA 200404023A ZA 200404023 B ZA200404023 B ZA 200404023B
- Authority
- ZA
- South Africa
- Prior art keywords
- formulation
- imaging
- stabilizing agent
- gum
- natural
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 188
- 238000009472 formulation Methods 0.000 title claims description 185
- 238000002405 diagnostic procedure Methods 0.000 title claims description 31
- 229920000161 Locust bean gum Polymers 0.000 claims description 88
- 235000010420 locust bean gum Nutrition 0.000 claims description 88
- 239000000711 locust bean gum Substances 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 87
- 239000000594 mannitol Substances 0.000 claims description 75
- 229930195725 Mannitol Natural products 0.000 claims description 74
- 235000010355 mannitol Nutrition 0.000 claims description 74
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 73
- 239000003381 stabilizer Substances 0.000 claims description 60
- 239000002357 osmotic agent Substances 0.000 claims description 55
- 238000003384 imaging method Methods 0.000 claims description 54
- 239000007864 aqueous solution Substances 0.000 claims description 40
- 239000012530 fluid Substances 0.000 claims description 34
- 238000002059 diagnostic imaging Methods 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000012636 positron electron tomography Methods 0.000 claims description 17
- 210000000813 small intestine Anatomy 0.000 claims description 15
- 150000004676 glycans Chemical class 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 238000002627 tracheal intubation Methods 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 10
- 239000000416 hydrocolloid Substances 0.000 claims description 10
- 208000025865 Ulcer Diseases 0.000 claims description 9
- 210000002784 stomach Anatomy 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 230000030136 gastric emptying Effects 0.000 claims description 7
- 210000003405 ileum Anatomy 0.000 claims description 7
- 210000001630 jejunum Anatomy 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 7
- 210000001165 lymph node Anatomy 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 210000005166 vasculature Anatomy 0.000 claims description 7
- 241001474374 Blennius Species 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 210000000416 exudates and transudate Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000000952 spleen Anatomy 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 238000012879 PET imaging Methods 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 206010000269 abscess Diseases 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 229960003276 erythromycin Drugs 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 4
- 240000008886 Ceratonia siliqua Species 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 230000036269 ulceration Effects 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 235000015125 Sterculia urens Nutrition 0.000 claims description 3
- 240000001058 Sterculia urens Species 0.000 claims description 3
- 240000004584 Tamarindus indica Species 0.000 claims description 3
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 210000004534 cecum Anatomy 0.000 claims description 3
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 210000002429 large intestine Anatomy 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 235000010491 tara gum Nutrition 0.000 claims description 3
- 239000000213 tara gum Substances 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 208000034158 bleeding Diseases 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 208000007784 diverticulitis Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 9
- 210000001124 body fluid Anatomy 0.000 claims 5
- 239000010839 body fluid Substances 0.000 claims 5
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 2
- 244000215068 Acacia senegal Species 0.000 claims 1
- 235000006491 Acacia senegal Nutrition 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 238000012831 peritoneal equilibrium test Methods 0.000 claims 1
- 238000012877 positron emission topography Methods 0.000 claims 1
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 1
- 239000002872 contrast media Substances 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 33
- 238000002595 magnetic resonance imaging Methods 0.000 description 26
- 238000002591 computed tomography Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 14
- 229940042003 metamucil Drugs 0.000 description 14
- 230000037406 food intake Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 229910052788 barium Inorganic materials 0.000 description 11
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229940039231 contrast media Drugs 0.000 description 8
- 239000000700 radioactive tracer Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 206010000060 Abdominal distension Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 206010028813 Nausea Diseases 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 229940061368 sonata Drugs 0.000 description 4
- 210000003384 transverse colon Anatomy 0.000 description 4
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013170 computed tomography imaging Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000000380 Nyssa aquatica Nutrition 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 210000001731 descending colon Anatomy 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- IAJILQKETJEXLJ-KKQCNMDGSA-N (2r,3r,4r,5s)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-KKQCNMDGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- -1 Metamucil® Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WGNIPWQCWPXQFL-UHFFFAOYSA-N [I].[Ba] Chemical compound [I].[Ba] WGNIPWQCWPXQFL-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- KJBLQGHJOCAOJP-UHFFFAOYSA-N metoclopramide hydrochloride Chemical compound O.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC KJBLQGHJOCAOJP-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003144 traumatizing effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33207401P | 2001-11-21 | 2001-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200404023B true ZA200404023B (en) | 2005-05-24 |
Family
ID=23296624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200404023A ZA200404023B (en) | 2001-11-21 | 2002-11-21 | Formulations for use in medical or diagnostic procedures. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7427391B2 (de) |
| EP (1) | EP1458328B1 (de) |
| JP (1) | JP4820054B2 (de) |
| KR (1) | KR20040071143A (de) |
| AU (1) | AU2002365395B2 (de) |
| BR (1) | BR0214314A (de) |
| CA (1) | CA2466808C (de) |
| IL (1) | IL162095A0 (de) |
| RU (1) | RU2004119035A (de) |
| WO (1) | WO2003045308A2 (de) |
| ZA (1) | ZA200404023B (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2466808C (en) * | 2001-11-21 | 2009-01-27 | E-Z-Em, Inc. | Formulations for use in medical or diagnostic procedures |
| US7378081B2 (en) * | 2003-01-29 | 2008-05-27 | Vincon Research Enterprises, Llc | Composition and method for direct visualization of the human appendix |
| US20050180920A1 (en) * | 2003-01-29 | 2005-08-18 | Vincenzo Giuliano | Oral contrast media composition for computerized axial tomographic examinations and method |
| US7657068B2 (en) * | 2003-02-05 | 2010-02-02 | Koninklijke Philips Electronics N.V. | Indication of accuracy of quantitative analysis |
| US7582283B2 (en) * | 2004-02-13 | 2009-09-01 | Wisconsin Alumni Research Foundation | Contrast agents to improve gastrointestinal tract opacification during abdominal and pelvic CT scans |
| EP1793860B1 (de) | 2004-07-15 | 2009-08-05 | GynaecologIQ B.V. | Zusammensetzung und verfahren zur medizinischen bilddarstellung von körperhöhlen |
| US9585973B1 (en) * | 2008-06-05 | 2017-03-07 | Peter Quagliano | Palatable liquid dilution vehicles for oral contrast agents |
| NL2003660C2 (en) | 2009-10-16 | 2011-04-19 | Giskit B V | Composition and method for medical imaging of body cavities. |
| EP2564875A4 (de) * | 2010-04-30 | 2016-03-30 | Ajinomoto Kk | Flüssigpräparat zur mündlichen verabreichung für ct-kolonographie sowie zusammensetzung zur abbildung des verdauungstrakts |
| KR20200125972A (ko) * | 2018-02-27 | 2020-11-05 | 트리스코 아이씨에이피 피티와이 리미티드 | 성분 |
| IT201900003113A1 (it) | 2019-03-04 | 2020-09-04 | Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologna | Bevanda coadiuvante |
| US11730831B2 (en) | 2019-03-26 | 2023-08-22 | Sicreations, Llc | Imaging agents and methods of using the same |
| AU2020283036A1 (en) | 2019-05-29 | 2022-01-20 | Sicreations, Llc | Methods for preserving a subject and using imaging contrast agents |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB657979A (en) * | 1948-07-03 | 1951-10-03 | Miles Lab | Improvements in or relating to x-ray contrast mediums |
| US3975512A (en) * | 1970-12-21 | 1976-08-17 | University Of Illinois Foundation | Non-toxic brominated perfluorocarbons radiopaque agents |
| US4074709A (en) * | 1976-04-15 | 1978-02-21 | Kaplan Leopold S | Method and device for facilitating double-contrast studies of the upper gastrointestinal tract |
| GB1599881A (en) * | 1977-02-02 | 1981-10-07 | Millington A R | Preparation for diagnostic radiology |
| US4448207A (en) * | 1981-11-03 | 1984-05-15 | Vital Metrics, Inc. | Medical fluid measuring system |
| DE3316703A1 (de) * | 1983-05-04 | 1984-11-08 | Schering AG, 1000 Berlin und 4709 Bergkamen | Orales kontrastmittel fuer die kernspintomographie und dessen herstellung |
| SE8601563D0 (sv) * | 1986-04-08 | 1986-04-08 | Carbomatrix Ab | Matrismaterial, forfarande for framstellning derav och anvendning derav |
| US5019059A (en) * | 1986-12-15 | 1991-05-28 | Uresil Corporation | Apparatus and method for collecting body fluids |
| US4930997A (en) * | 1987-08-19 | 1990-06-05 | Bennett Alan N | Portable medical suction device |
| AU4492989A (en) * | 1988-10-20 | 1990-05-14 | Fusen H. Chen | Incontinence device |
| US5783171A (en) * | 1989-06-16 | 1998-07-21 | Neorx Corporation | Radionuclide metal N2 S2 chelates substituted with glucose and biotin moieties |
| GB8916782D0 (en) * | 1989-07-21 | 1989-09-06 | Nycomed As | Compositions |
| US4957486A (en) * | 1989-10-02 | 1990-09-18 | Davis Emsley A | Rectal-stomal insert apparatus and method |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5368840A (en) * | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
| US5107842A (en) * | 1991-02-22 | 1992-04-28 | Molecular Biosystems, Inc. | Method of ultrasound imaging of the gastrointestinal tract |
| US5179955A (en) | 1991-02-22 | 1993-01-19 | Molecular Biosystems, Inc. | Method of abdominal ultrasound imaging |
| JP3238485B2 (ja) * | 1992-08-07 | 2001-12-17 | 明治乳業株式会社 | 消化管造影用組成物 |
| US5380522A (en) | 1992-08-11 | 1995-01-10 | Day; Charles E. | Method for treatment of irritable bowel syndrome |
| WO1994007417A1 (en) * | 1992-10-06 | 1994-04-14 | Molecular Biosystems, Inc. | Method of ultrasonic imaging of body cavities |
| JPH06157355A (ja) * | 1992-11-13 | 1994-06-03 | Dai Ichi Seiyaku Co Ltd | Ｍｒｉ用粒状製剤 |
| CA2182213A1 (en) * | 1994-01-28 | 1995-08-03 | William George Gorman | Oral magnetic particle formulation |
| US5611342A (en) * | 1994-02-15 | 1997-03-18 | Molecular Biosystems, Inc. | Method of computer tomography imaging the gastrointestinal tract and surrounding upper abdominal tissues and organs using an orally administered low density contrast medium |
| US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
| DE4424233C1 (de) * | 1994-07-09 | 1995-12-07 | Thomas Gieselmann | Orales Echokontrastmittel für Ultraschalldiagnostik |
| US5782762A (en) * | 1994-10-27 | 1998-07-21 | Wake Forest University | Method and system for producing interactive, three-dimensional renderings of selected body organs having hollow lumens to enable simulated movement through the lumen |
| US6066139A (en) * | 1996-05-14 | 2000-05-23 | Sherwood Services Ag | Apparatus and method for sterilization and embolization |
| US5779662A (en) * | 1996-05-20 | 1998-07-14 | Linvatec Corporation | Laparoscopic tissue resection system |
| AU746790B2 (en) * | 1996-09-10 | 2002-05-02 | Medinox, Inc. | Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications |
| EP0959693A1 (de) * | 1997-01-31 | 1999-12-01 | Fmc Corporation | Textur- und stabilsatorzusammensetzung |
| GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| CN1233505A (zh) * | 1998-04-24 | 1999-11-03 | 胡挽华 | 一种胃肠阴性造影剂及其生产方法 |
| US6214376B1 (en) * | 1998-08-25 | 2001-04-10 | Banner Pharmacaps, Inc. | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture |
| JP3099293B2 (ja) * | 1999-02-12 | 2000-10-16 | イトー海外事業株式会社 | 可食印刷用シート及びその製造装置並びに製造方法 |
| JP2001048810A (ja) * | 1999-08-04 | 2001-02-20 | Ina Food Ind Co Ltd | 造影剤用増粘剤 |
| IN192748B (de) * | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
| CA2424730A1 (en) * | 2000-10-02 | 2002-04-11 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for the transport of biologically active agents across cellular barriers |
| CN1543337A (zh) | 2001-08-16 | 2004-11-03 | ���ո����ɸߵȽ�����ίԱ�������� | 可膨胀的胃潴留装置 |
| CA2466808C (en) * | 2001-11-21 | 2009-01-27 | E-Z-Em, Inc. | Formulations for use in medical or diagnostic procedures |
-
2002
- 2002-11-21 CA CA002466808A patent/CA2466808C/en not_active Expired - Lifetime
- 2002-11-21 US US10/476,314 patent/US7427391B2/en not_active Expired - Lifetime
- 2002-11-21 WO PCT/US2002/037385 patent/WO2003045308A2/en active Application Filing
- 2002-11-21 RU RU2004119035/15A patent/RU2004119035A/ru not_active Application Discontinuation
- 2002-11-21 EP EP02804018A patent/EP1458328B1/de not_active Expired - Lifetime
- 2002-11-21 AU AU2002365395A patent/AU2002365395B2/en not_active Expired
- 2002-11-21 IL IL16209502A patent/IL162095A0/xx unknown
- 2002-11-21 KR KR10-2004-7007813A patent/KR20040071143A/ko not_active Application Discontinuation
- 2002-11-21 JP JP2003546813A patent/JP4820054B2/ja not_active Expired - Lifetime
- 2002-11-21 ZA ZA200404023A patent/ZA200404023B/en unknown
- 2002-11-21 BR BR0214314-3A patent/BR0214314A/pt not_active IP Right Cessation
-
2008
- 2008-09-19 US US12/234,147 patent/US8343462B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005510531A (ja) | 2005-04-21 |
| US7427391B2 (en) | 2008-09-23 |
| EP1458328A4 (de) | 2009-06-17 |
| US8343462B2 (en) | 2013-01-01 |
| BR0214314A (pt) | 2004-11-09 |
| WO2003045308A3 (en) | 2003-12-18 |
| EP1458328B1 (de) | 2013-01-30 |
| JP4820054B2 (ja) | 2011-11-24 |
| WO2003045308A2 (en) | 2003-06-05 |
| CA2466808A1 (en) | 2003-06-05 |
| AU2002365395A1 (en) | 2003-06-10 |
| AU2002365395B2 (en) | 2006-07-20 |
| IL162095A0 (en) | 2005-11-20 |
| US20040241093A1 (en) | 2004-12-02 |
| EP1458328A2 (de) | 2004-09-22 |
| CA2466808C (en) | 2009-01-27 |
| US20090180963A1 (en) | 2009-07-16 |
| KR20040071143A (ko) | 2004-08-11 |
| RU2004119035A (ru) | 2005-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8343462B2 (en) | Formulations for use in medical and diagnostic procedures | |
| Lauenstein et al. | Optimization of oral contrast agents for MR imaging of the small bowel | |
| US20090136426A1 (en) | Contrast media for using in medical and diagnostic procedures and methods of using the same | |
| CN107847445B (zh) | 包封的气体或部分真空ct造影材料 | |
| Ajaj et al. | Oral contrast agents for small bowel distension in MRI: influence of the osmolarity for small bowel distention | |
| CN108743976A (zh) | 基于低-z原子的肠ct造影材料 | |
| JP2005510531A5 (de) | ||
| Kinner et al. | MRI of the small bowel: can sufficient bowel distension be achieved with small volumes of oral contrast? | |
| Borthne et al. | Osmolarity: a decisive parameter of bowel agents in intestinal magnetic resonance imaging | |
| US7582283B2 (en) | Contrast agents to improve gastrointestinal tract opacification during abdominal and pelvic CT scans | |
| US20220401587A1 (en) | Low x-ray attenuation change hard shelled oral contrast material | |
| Shi et al. | Magnesium sulfate as an oral contrast medium in magnetic resonance imaging of the small intestine | |
| Paterson et al. | The pros and cons of imaging options | |
| Мещеряков et al. | Comparison of laxatives used in CT colonography with full bowel preparation | |
| Oh-oka et al. | Usefulness of MR-seminography using Gd-DTPA in intermediate magnetic field MRI equipment | |
| Steingötter | Magnetic resonance imaging for the analysis of human gastric motor activity, intragastric distribution and related emptying | |
| Hall | Scientific Programme Abstracts |